Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 5
1986 45
1987 56
1988 109
1989 257
1990 298
1991 238
1992 177
1993 193
1994 220
1995 241
1996 258
1997 281
1998 290
1999 290
2000 319
2001 332
2002 320
2003 318
2004 318
2005 362
2006 406
2007 406
2008 449
2009 478
2010 478
2011 533
2012 625
2013 677
2014 697
2015 781
2016 776
2017 655
2018 666
2019 369
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

11,872 results
Results by year
Filters applied: . Clear all
Page 1
Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.
Lee YR, Chen M, Lee JD, Zhang J, Lin SY, Fu TM, Chen H, Ishikawa T, Chiang SY, Katon J, Zhang Y, Shulga YV, Bester AC, Fung J, Monteleone E, Wan L, Shen C, Hsu CH, Papa A, Clohessy JG, Teruya-Feldstein J, Jain S, Wu H, Matesic L, Chen RH, Wei W, Pandolfi PP. Lee YR, et al. Science. 2019 May 17;364(6441):eaau0159. doi: 10.1126/science.aau0159. Science. 2019. PMID: 31097636 Free PMC article.
SUMO protease SENP1 deSUMOylates and stabilizes c-Myc.
Sun XX, Chen Y, Su Y, Wang X, Chauhan KM, Liang J, Daniel CJ, Sears RC, Dai MS. Sun XX, et al. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):10983-10988. doi: 10.1073/pnas.1802932115. Epub 2018 Oct 10. Proc Natl Acad Sci U S A. 2018. PMID: 30305424 Free PMC article.
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dunleavy K, et al. Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. Lancet Haematol. 2018. PMID: 30501868 Free PMC article. Clinical Trial.
Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
Ting CY, Chang KM, Kuan JW, Sathar J, Chew LP, Wong OJ, Yusuf Y, Wong L, Samsudin AT, Pana MNBM, Lee SK, Gopal NSR, Puri R, Ong TC, Bahari SK, Goh AS, Teoh CS. Ting CY, et al. Int J Med Sci. 2019 Apr 20;16(4):556-566. doi: 10.7150/ijms.27610. eCollection 2019. Int J Med Sci. 2019. PMID: 31171907 Free PMC article.
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.
Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. Vaseva AV, et al. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. Cancer Cell. 2018. PMID: 30423298 Free PMC article.
11,872 results
Jump to page
Feedback